The effects of simvastatin and fenofibrate on malondialdehyde and reduced glutathione concentrations in the plasma, liver, and brain of normolipidaemic and hyperlipidaemic rats

Vukšić, Antonija; Rašić, Dubravka; Žunec, Suzana; Božina, Tamara; Konjevoda, Paško; Lovrić, Jasna; Bilušić, Marinko; Bradamante, Vlasta

doi:10.2478/aiht-2023-74-3697

Abstract

The objective of study was to investigate the effects of different doses of simvastatin and fenofibrate on malondialdehyde (MDA) and reduced glutathione (GSH) in the plasma, liver, and brain tissue of male normolipidaemic and hyperlipidaemic rats. Normolipidaemic (Wistar) rats were receiving 10 or 50 mg/kg a day of simvastatin or 30 or 50 mg/kg a day of fenofibrate. Hyperlipidaemic (Zucker) rats were receiving 50 mg/kg/day of simvastatin or 30 mg/kg/day of fenofibrate. Control normolipidaemic and hyperlipidaemic rats were receiving saline. Simvastatin, fenofibrate, and saline were administered by gavage for three weeks. In normolipidaemic rats simvastatin and fenofibrate showed similar and dose-independent effects on plasma and brain MDA and GSH concentrations. Generally, plasma and brain MDA decreased, while brain GSH concentration increased. In hyperlipidaemic rats simvastatin did not affect plasma and brain MDA and GSH concentrations but significantly decreased liver GSH. Fenofibrate decreased plasma and liver MDA but increased brain MDA. In both rat strains fenofibrate significantly decreased liver GSH concentrations, most likely because fenofibrate metabolites bind to GSH. Our findings suggest that simvastatin acts as an antioxidant only in normolipidaemic rats, whereas fenofibrate acts as an antioxidant in both rat strains.

References

Parums DV. Editorial: The 2021 European Society of Cardiology (ESC) guidelines on the real-world prevention of atherosclerotic cardiovascular disease (ASCVD). Med Sci Monit 2021;27:e9351721–3. doi: 10.12659/MSM.935172
Open DOI Search in Google Scholar Back to article
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian B. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;140(11):e596-e646. doi: 10.1161/CIR.0000000000000678
Open DOI Search in Google Scholar Back to article
Bedi O, Dhawan V, Sharma PL, Kumar P. Pleiotropic effects of statins: new therapeutic targets in drug design. Naunyn Schmiedebergs Arch Pharmacol 2016;389:695–712. doi: 10.1007/s00210-016-1252-4
Open DOI Search in Google Scholar Back to article
Botta M, Audano M, Sahebkar A, Sirtori CR, Mitro N, Ruscica M. PPAR agonists and metabolic syndrome: an established role? Int J Mol Sci 2018;19(4):1197. doi: 10.3390/ijms19041197
Open DOI Search in Google Scholar Back to article
Ali FY, Armstrong PC, Dhanji AR, Tucker AT, Paul-Clark MJ, Mitchell JA, Warner TD. Antiplatelet actions of statins and fibrates are mediated by PPARs. Arterioscler Thromb Vasc Biol 2009;29:706–11. doi: 10.1161/ATVBAHA.108.183160
Open DOI Search in Google Scholar Back to article
Sahebkar A, Serban MC, Mikhailidis DP, Toth PP, Muntner P, Ursoniu S, Mosterou S, Glasser S, Martin SS, Jones SR, Rizzo M, Rysz J, Sniderman AD, Pencina MJ, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis. Pharmacol Res 2016;103:236–52. doi: 10.1016/j.phrs.2015.12.001
Open DOI Search in Google Scholar Back to article
Navarese EP, Buffon A, Andreotti F, Kozinski M, Welton N, Fabiszak T, Caputo S, Grzesk G, Kubica A, Swiatkiewicz I, Sukiennik A, Kelm M, De Servi S, Kubica J. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol 2013;111:1123–30. doi: 10.1016/j.amjcard.2012.12.037
Open DOI Search in Google Scholar Back to article
Okuyama H, Langsjoen PH, Hamazaki T, Ogushi Y, Hama R, Kobayashi T, Uchino H. Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms. Expert Rev Clin Pharmacol 2015;8:189–99. doi: 10.1586/17512433.2015.1011125
Open DOI Search in Google Scholar Back to article
Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088–93. doi: 10.1161/01.cir.98.19.2088
Open DOI Search in Google Scholar Back to article
Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, Najib-Fruchart J, Glineur C, Staels B. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest 2001;107:1423–32. doi: 10.1172/JCI10852
Open DOI Search in Google Scholar Back to article
Wójtowicz S, Strosznajder AK, Jeżyna M, Strosznajder JB. The novel role of PPAR alpha in the brain: promising target in therapy of Alzheimer’s disease and other neurodegenerative disorders. Neurochem Res 2020;45:972–88. doi: 10.1007/s11064-020-02993-5
Open DOI Search in Google Scholar Back to article
Hong K-S, Lee JS. Statins in acute ischemic stroke: a systematic review. J Stroke 2015;17:282–301. doi: 10.5853/jos.2015.17.3.282
Open DOI Search in Google Scholar Back to article
Chataway J, Schuerer N, Alsanousi A, Chan D, MacManus D, Hunter K, Anderson V, Bangham CR, Clegg S, Nielsen C, Fox NC, Wilkie D, Nicholas JM, Calder VL, Greenwood J, Frost C, Nicholas R. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet 2014;383:2213–21. doi: 10.1016/S0140-6736(13)62242-4
Open DOI Search in Google Scholar Back to article
Lee Y-C, Lin C-H, Wu R-M, Lin M-S, Lin J-W, Chang C-H, Lai M-S. Discontinuation of statin therapy associates with Parkinson disease: a population-based study. Neurology 2013;81:410–6. doi: 10.1212/WNL.0b013e31829d873c
Open DOI Search in Google Scholar Back to article
Shinohara M, Sato N, Shimamura M, Kurinami H, Hamasaki T, Chatterjee A, Rakugi H, Morishita R. Possible modification of Alzheimer’s disease by statins in midlife: interactions with genetic and non-genetic risk factors. Front Aging Neurosci 2014;6:71. doi: 10.3389/fnagi.2014.00071
Open DOI Search in Google Scholar Back to article
Losey P, Ladds E, Laprais M, Guevel B, Burns L, Bordet R, Anthony DC. The role of PPAR activation during the systemic response to brain injury. J Neuroinflammation 2015;12:99. doi: 10.1186/s12974-015-0295-7
Open DOI Search in Google Scholar Back to article
Chen XR, Besson VC, Beziaud T, Plotkine M, Marchand-Leroux C. Combination therapy with fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, and simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, on experimental traumatic brain injury. J Pharmacol Exp Ther 2008;326:966–74. doi: 10.1124/jpet.108.140368
Open DOI Search in Google Scholar Back to article
Frijhoff J, Winyard PG, Zarkovic N, Davies SS, Stocker R, Cheng D Knight AR, Taylor EL, Oettrich J, Ruskovska T, Gasparovic AC, Cuadrado A, Weber D, Poulsen HE, Grune T, Schmidt HH, Ghezzi P. Clinical relevance of biomarkers of oxidative stress. Antioxid Redox Signal 2015;23:1144–70. doi: 10.1089/ars.2015.6317
Open DOI Search in Google Scholar Back to article
Aoyama K. Glutathione in the brain. Int J Mol Sci 2021;22(9):5010. doi: 10.3390/ijms22095010
Open DOI Search in Google Scholar Back to article
Lu SC. Regulation of glutathione synthesis. Mol Aspects Med 2009;30:42–59. doi: 10.1016/j.mam.2008.05.005
Open DOI Search in Google Scholar Back to article
Macan M, Vukšić A, Žunec S, Konjevoda P, Lovrić J, Kelava M, Štambuk N, Vrkić N, Bradamante V. Effects of simvastatin on malondialdehyde level and esterase activity in plasma and tissue of normolipidaemic rats. Pharmacol Rep 2015;67:907–13. doi: 10.1016/j.pharep.2015.02.005
Open DOI Search in Google Scholar Back to article
Mohamadin AM, Elberry AA, Abdel Gawad HS, Morsy GM, Al-Abbasi FA. Protective effects of simvastatin, a lipid lowering agent, against oxidative damage in experimental diabetic rats. J Lipids 2011;2011:167958. doi: 10.1155/2011/167958
Open DOI Search in Google Scholar Back to article
Zeng H, Liu Z. Atorvastatin induces hepatotoxicity in diabetic rats via oxidative stress, inflammation, and anti-apoptotic pathway. Med Sci Monit 2019;25:6165–73. doi: 10.12659/MSM.915790
Open DOI Search in Google Scholar Back to article
Bełtowski J, Wójcicka G, Mydlarczyk M, Jamroz A. The effect of peroxisome proliferator-activated receptors alpha (PPARalpha) agonist, fenofibrate, on lipid peroxidation, total antioxidant capacity, and plasma paraoxonase 1 (PON 1) activity. J Physiol Pharmacol 2002;53:463–75. PMID: 12369742
Search in Google Scholar Back to article
Macan M, Konjevoda P, Lovrić J, Koprivanac M, Kelava M, Vrkić N, Bradamante V. The influence of gemfibrozil on malondialdehyde level and paraoxonase 1 activity in Wistar and fisher rats. Basic Clin Pharmacol Toxicol 2011;108:428–35. doi: 10.1111/j.1742-7843.2011. 00674.x
Open DOI Search in Google Scholar Back to article
Ciriolo MR, Mavelli I, Rotilio G, Borzatta V, Cristofari M, Stanzani L. Decrease of superoxide dismutase and glutathione peroxidase in liver of rats treated with hypolipidaemic drugs. FEBS Lett 1982;144:264–8. doi: 10.1016/0014-5793(82)80651-0
Open DOI Search in Google Scholar Back to article
Ciriolo MR, Rossi L, Mavelli I, Rotilio G, Borzatta V, Cristofori M, Barbanti M. The effects of hypolipidaemic agents derived from procetofenic acid on the activity of superoxide dismutase and glutathione peroxidase and on malonyl dialdehyde production of rat liver. Arzneimittelforschung 1984;34:465–7. PMID: 6540105
Search in Google Scholar Back to article
Abdoli N, Heidari R, Azarmi Y, Eghbal MA. Mechanisms of the statins cytotoxicity in freshly isolated rat hepatocytes. J Biochem Mol Toxicol 2013;27:287–94. doi: 10.1002/jbt.21485
Open DOI Search in Google Scholar Back to article
Eghbal MA, Abdoli N, Azarmi Y. Efficiency of hepatocyte pretreatment with coenzyme Q₁₀ against statin toxicity. Arh Hig Rada Toksikol 2014;65:101–8. doi: 10.2478/10004-1254-65-2014-2398
Open DOI Search in Google Scholar Back to article
Yaribeygi H, Mohammadi MT, Rezaee R, Sahebkar A. Fenofibrate improves renal function by amelioration of NOX-4, IL-18, and p53 expression in an experimental model of diabetic nephropathy. J Cell Biochem 2018;119:7458–69. doi: 10.1002/jcb.27055
Open DOI Search in Google Scholar Back to article
Wood WG, Eckert GP, Igbavboa U, Müller WE. Statins and neuroprotection: a prescription to move the field forward. Ann N Y Acad Sci 2010;1199:69–76. doi: 10.1111/j.1749-6632.2009.05359.x
Open DOI Search in Google Scholar Back to article
Deplanque D, Gelé P, Pétrault O, Six I, Furman C, Bouly M, Nion S, Dupuis B, Leys D, Fruchart JC, Cecchelli R, Staels B, Duriez P, Bordet R. Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci 2003;23:6264–71. doi: 10.1523/JNEUROSCI.23-15-06264.2003
Open DOI Search in Google Scholar Back to article
Balakumar P, Varatharajan R, Nyo YH, Renushia R, Raaginey D, Oh AN, Akhtar SS, Rupeshkumar M, Sundram K, Dhanaraj SA. Fenofibrate and dipyridamole treatments in low-doses either alone or in combination blunted the development of nephropathy in diabetic rats. Pharmacol Res 2014;90:36–47. doi: 10.1016/j.phrs.2014.08.008
Open DOI Search in Google Scholar Back to article
Fatani SH, Naderaralli EK, Panchiani S, Shah F, Wong C. The effects of dietary obesity on protein expressions of insulin signalling pathway in rat aorta. Drug Discov Ther 2008;2:256–61. PMID: 22504637
Search in Google Scholar Back to article
Nezić L, Skrbić R, Dobrić S, Stojiljković MP, Jaćević V, Stoisavljević Satara S, Milovanović ZA, Stojaković N. Simvastatin and indomethacin have similar anti-inflammatory activity in a rat model of acute local inflammation. Basic Clin Pharmacol Toxicol 2009;104:185–91. doi: 10.1111/j.1742-7843.2008.00302.x
Open DOI Search in Google Scholar Back to article
Simsek Ozek N, Burak Bal I, Yildirim S, Rustu Inur, Severcan F. Structural and functional characterization of simvastatin-induced myotoxicity in different skeletal muscles. Biochim Biophys Acta 2014;1840:406–14. doi: 10.1016/j.bbagen.2013.09.010
Open DOI Search in Google Scholar Back to article
Pravilnik o zaštiti životinja koje se koriste u znanstvene svrhe [Regulation of the protection of animals used for scientific purposes, in Croatian]. Narodne novine 55/2013.
Search in Google Scholar Back to article
Guillen J. FELASA guidelines and recommendations. J Am Assoc Lab Anim Sci 2012;51:311–21. PMCID: PMC3358979
Search in Google Scholar Back to article
Drury JA, Nycyk JA, Cooke RW. Comparison of urinary and plasma malondialdehyde in preterm infants. Clin Chim Acta 1997;263:177–85. doi: 10.1016/s0009-8981(97)00051-x
Open DOI Search in Google Scholar Back to article
Ellman GL. A colorimetric method for determining low concentrations of mercaptans. Arch Biochem Biophys 1958;74:443–50. doi: 10.1016/0003-9861(58)90014-6
Open DOI Search in Google Scholar Back to article
Rowe P. Essential Statistics for the Pharmaceutical Sciences. Chichester: Wiley; 2007. ISBN: 9780470034682
Search in Google Scholar Back to article
Bełtowski J, Wójcicka G, Mydlarczyk M, Jamroz A. Cerivastatin modulates plasma paraoxonase/arylesterase activity and oxidant-antioxidant balance in the rat. Pol J Pharmacol 2002;54:143–50. PMID: 12139111
Search in Google Scholar Back to article
Liang H, Feng Y, Cui R, Qiu M, Zhang J, Liu C. Simvastatin protects against acetaminophen-induced liver injury in mice. Biomed Pharmacother 2018;98:916–24. doi: 10.1016/j.biopha. 2017.12076
Open DOI Search in Google Scholar Back to article
Zhang F, Sun D, Chen J, Guan N, Huo X, Xi H. Simvastatin attenuates angiotensin II-induced inflammation and oxidative stress in human mesangial cells. Mol Med Rep 2015;11:1246–51. doi: 10.3892/mmr.2014-2871
Open DOI Search in Google Scholar Back to article
Zinellu A, Mangoni AA. A systematic review and meta-analysis of the effect of statins on glutathione peroxidase, superoxide dismutase, and catalase. Antioxidants (Basel) 2021;10(11):1841. doi: 10.3390/antiox10111841
Open DOI Search in Google Scholar Back to article
Verma K, Makwana S, Paliwal S, Paliwal V, Jain S, Paliwal S, Sharma S. Simvastatin ameliorates oxidative stress levels in HepG2 cells and hyperlipidaemic rats. Curr Res Pharmacol Drug Discov 2022;3:100088. doi: 10.1016/j.crphar.2022.100088
Open DOI Search in Google Scholar Back to article
Wahba MGF, Messiha BAS, Abo-Saif AA. Protective effects of fenofibrate and resveratrol in an aggressive model of rheumatoid arthritis in rats. Pharm Biol 2016;54:1705–15. doi: 10.3109/13880209. 2015.1125931
Open DOI Search in Google Scholar Back to article
Aberg F, Appelkvist EL. Clofibrate and di(2-ethylhexyl) phthalate increase ubiquinone contents without affecting cholesterol levels. Acta Biochim Pol 1994;41:321–9. PMID: 7856403
Search in Google Scholar Back to article
Arnaiz LS, Travacio M, Monserrat AJ, Cutrín JC, Llesuy S, Boveris A. Chemiluminescence and antioxidant levels during peroxisome proliferation by fenofibrate. Biochim Biophys Acta 1997;1360:222–8. doi: 10.1016/s0925-4439(97)00004-5
Open DOI Search in Google Scholar Back to article
Tkác I, Molcányiová A, Javorský M, Kozárová M. Fenofibrate treatment reduces circulating conjugated diene level and increases glutathione peroxidase activity. Pharmacol Res 2006;53:261–4. doi: 10.1016/j.phrs.2005.12.002
Open DOI Search in Google Scholar Back to article
Jiao H-L, Zhao B-L. Cytotoxic effect of peroxisome proliferator fenofibrate on human HepG2 hepatoma cell line and relevant mechanisms. Toxicol Appl Pharmacol 2002;185:172–9. doi: 10.1006/taap.2002.9538
Open DOI Search in Google Scholar Back to article
Shore LJ, Fenselau C, King AR, Dickinson RG. Characterization and formation of the glutathione conjugate of clofibric acid. Drug Metab Dispos 1995;23:119–23. PMID: 7720514
Search in Google Scholar Back to article
Sun B, Xie Y, Jiang J, Wang Y, Xu X, Zhao C, Huang F. Pleiotropic effects of fenofibrate therapy on rats with hypertriglycemia. Lipids Health Dis 2015;14:27. doi: 10.1186/s12944-015-0032-3
Open DOI Search in Google Scholar Back to article

The effects of simvastatin and fenofibrate on malondialdehyde and reduced glutathione concentrations in the plasma, liver, and brain of normolipidaemic and hyperlipidaemic rats

Abstract

Paradigm

My account